Mesothelioma Damages Recalculation in 2026: How CheckMate 743's 14% Five-Year Survival Changes Lost-Earnings Projections

Why Does New Mesothelioma Survival Data Matter for Damages Calculations?

Damages testimony in mesothelioma cases — civil litigation against still-solvent defendants, not flat-schedule trust fund claims — almost always turns on three calculations: lost earnings, future medical costs, and pain-and-suffering damages. Each of those calculations depends on a life-expectancy projection. And life expectancy in mesothelioma has moved.

For roughly 16 years after the FDA approved pemetrexed plus cisplatin in 2004, that combination chemotherapy was the only first-line systemic treatment for unresectable pleural mesothelioma. The Vogelzang 2003 trial that supported the approval reported median overall survival of 12.1 months — and that number, with modest updates, anchored damages testimony for nearly two decades [4]. SEER data from the same era reported five-year survival rates under 5% for pleural mesothelioma [6].

That picture changed in October 2020, when the FDA approved nivolumab plus ipilimumab as first-line therapy on the strength of the original CheckMate 743 readout [3, 7]. It changed again in April 2024, when ATOMIC-Meso reported the first positive Phase 3 result in nonepithelioid disease [2]. And it changed most consequentially for damages experts in March 2026, when the CheckMate 743 five-year follow-up published in the Journal of Clinical Oncology confirmed that the survival benefit holds at five years and beyond [1].

Damages projections that still anchor to pre-2020 numbers are not just out of date. They are wrong in a direction that costs plaintiffs money.

"I have read damages reports from defense experts in 2025 and 2026 that cite Vogelzang 2003 as if nothing had happened in the intervening 22 years. Two FDA-approved immunotherapy combinations, a Phase 3 success in nonepithelioid disease, a five-year update showing durable benefit — none of it in the report. That is not conservative actuarial work. That is selective evidence selection."

— Paul Danziger, Founding Partner, Danziger & De Llano

What Did CheckMate 743's Five-Year Update Reveal in 2026?

The CheckMate 743 trial randomized 605 patients with previously untreated unresectable malignant pleural mesothelioma to first-line nivolumab plus ipilimumab or platinum-based chemotherapy [3]. The primary readout in 2021 demonstrated a median overall survival of 18.1 months on immunotherapy versus 14.1 months on chemotherapy, with a hazard ratio for death of 0.74 [3]. The FDA had approved the combination based on an interim analysis the prior year [7].

The five-year update published in the Journal of Clinical Oncology in March 2026, with a median follow-up of 66.8 months, reported the headline number that now belongs in every damages report: five-year overall survival was 14% on nivolumab plus ipilimumab versus 6% on chemotherapy [1]. The hazard ratio for death was 0.74, with a 95% confidence interval of 0.62 to 0.88 [1]. The benefit held across tumor histologic subtypes. After adjusting for the 24% of chemotherapy-arm patients who received subsequent immunotherapy, the hazard ratio strengthened to 0.64 [1].

For a damages expert, the relevant translation is this: a randomly selected mesothelioma plaintiff treated with current first-line immunotherapy has roughly a one-in-seven chance of being alive at five years. That probability anchors a different damages model than the one anchored on a less-than-one-in-twenty probability.

How Does ATOMIC-Meso Change Projections for Nonepithelioid Patients?

Mesothelioma has three histologic subtypes. Epithelioid disease, the most common, has the best baseline prognosis. Sarcomatoid disease has the worst. Biphasic disease falls in between. Together, sarcomatoid and biphasic — the nonepithelioid subtypes — account for roughly 35% of pleural mesothelioma diagnoses and have historically been excluded from or underrepresented in the major trials.

The ATOMIC-Meso Phase 2-3 trial published in JAMA Oncology in April 2024 enrolled 249 chemotherapy-naive patients with confirmed nonepithelioid pleural mesothelioma at 43 centers across five countries [2]. It tested pegargiminase — a pegylated bacterial enzyme that depletes circulating arginine — added to first-line pemetrexed plus platinum chemotherapy. The trial met its primary endpoint of overall survival: median 9.3 months on pegargiminase versus 7.7 months on placebo, hazard ratio 0.71, P=.02 [2]. Median progression-free survival, the secondary endpoint, also improved (6.2 versus 5.6 months, hazard ratio 0.65, P=.02) [2]. The full canonical reference is documented at WikiMesothelioma's ATOMIC-Meso Trial entry.

For damages experts working with a sarcomatoid or biphasic plaintiff, ATOMIC-Meso is the first Phase 3 result to incorporate. A 29% reduction in the risk of death is the number that updates the actuarial projection. The pre-ATOMIC-Meso default — which essentially gave nonepithelioid plaintiffs the survival numbers of the worst arm of every trial they had been excluded from — is no longer defensible.

"We see this most acutely with sarcomatoid clients. For two decades the defense damages number on a sarcomatoid plaintiff was anchored to the assumption that this patient would not respond to anything. ATOMIC-Meso is the trial that ends that assumption. The 9.3-month median is not a cure, but it is a meaningful, statistically significant survival benefit in the hardest subgroup we have."

— Paul Danziger, Founding Partner, Danziger & De Llano

How Are Damages Models Anchored to Pre-2020 Data Underestimating Recovery?

Damages modeling in personal injury litigation typically calculates four major categories:

• Lost past earnings — wages and benefits lost between diagnosis and trial
• Lost future earnings — wages and benefits the plaintiff would have earned over remaining work-life expectancy
• Future medical and care costs — projected oncology care, palliative care, home health, and family caregiver burden
• Pain and suffering / loss of enjoyment of life — non-economic damages over remaining lifespan

Three of those four categories scale directly with projected remaining life expectancy. If the projection is six months too short, the lost-earnings calculation drops a half-year of wages, the future medical cost calculation drops a half-year of oncology billing, and the pain-and-suffering calculation drops a half-year of damages.

The CheckMate 743 five-year curve tells damages experts something specific: meaningful numbers of patients survive substantially past the older median estimates. The trial's tail is not zero. Damages experts using fixed median life-expectancy assumptions — rather than weighted expected-value calculations from a current survival curve — are leaving real money on the table for plaintiffs.

Which Damages Categories Are Affected Most by Extended Survival?

The damages categories most sensitive to updated survival data, in approximate order:

1. Future medical and care costs. Modern immunotherapy regimens are expensive — nivolumab plus ipilimumab approaches six-figure annual drug costs at list price — and the patients who benefit are now receiving them for years rather than months. The cost projection has to incorporate both the higher per-year cost and the longer duration.
2. Pain and suffering / loss of enjoyment. These damages accrue over time. Extended survival multiplies the totals. Juries who hear a plaintiff project a meaningful chance of living three to five years rather than one assign different non-economic damages.
3. Lost future earnings. For younger plaintiffs — and mesothelioma is no longer an exclusively elderly disease, with secondary exposure cases regularly involving plaintiffs in their fifties — the difference between a 12-month and a 36-month life-expectancy projection is enormous on the lost-future-earnings line item.
4. Family caregiver damages. Where the jurisdiction allows them, family caregiver compensation accrues over the projected illness period.

How Should Plaintiffs and Their Attorneys Adjust Damages Projections in 2026?

The practical adjustment is straightforward in shape but requires evidence: damages experts should anchor mesothelioma life-expectancy testimony to the current treatment-stratified survival curves rather than to single median numbers from twenty-year-old trials. For an unresectable pleural plaintiff being treated with first-line immunotherapy, the CheckMate 743 five-year curve [1] is the right anchor. For a nonepithelioid plaintiff on pegargiminase plus chemotherapy, the ATOMIC-Meso overall survival curve [2] applies. For a peritoneal plaintiff undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), the relevant body of evidence is the cytoreductive-surgery cohort literature.

Where defense damages experts continue to cite pre-2020 actuarial numbers, plaintiff attorneys should be prepared to cross-examine on (a) the date of the cited evidence, (b) whether the cited evidence predates FDA-approved first-line immunotherapy, and (c) whether the projection accommodates current treatment options the plaintiff is actually receiving or eligible for. The mesothelioma damages framework at Danziger & De Llano walks through how those cross-examinations are structured in practice.

For a deeper canonical reference on the immunotherapy combination at the center of these calculations, see CheckMate 743 Trial. For the nonepithelioid Phase 3 evidence base, see ATOMIC-Meso Trial.

"The discipline I push every damages expert we work with: do not cite a median. Cite a curve. The CheckMate 743 five-year update is a curve, and the area under that curve is where the damages live. A defense expert citing Vogelzang 2003 is citing a curve too — just an obsolete one. Make the jury see both."

— Paul Danziger, Founding Partner, Danziger & De Llano

What Does This Mean for Asbestos Trust Fund and Settlement Strategy?

Mesothelioma compensation comes from two main paths. Asbestos trust funds established under Section 524(g) of the U.S. Bankruptcy Code hold more than $30 billion across 60+ active trusts, paying out on disease-tier schedules that do not move with new survival evidence. Civil litigation against still-solvent asbestos manufacturers, suppliers, and premises owners is the second path, and that is where the 2026 survival data lands directly — on damages testimony, on settlement negotiations with current defendants, and on jury verdicts.

The two paths are not alternatives. Most mesothelioma plaintiffs file claims against multiple bankrupt-company trusts simultaneously while their civil action proceeds against current defendants. The trust fund recoveries provide near-term cash flow that helps cover treatment costs — including the cost of accessing modern immunotherapy regimens, which insurance does not always fully cover. The civil settlement or verdict, when it comes, incorporates the damages calculations that current evidence will support. Outcomes vary by case, and in a number of states (including Texas, Ohio, West Virginia, Wisconsin, Arizona, and Mississippi) statutory setoffs and trust-disclosure requirements affect how parallel recoveries interact with civil verdicts; experienced counsel handles the disclosure and apportionment work in each jurisdiction.

For mesothelioma plaintiffs and their families navigating both treatment access and compensation strategy, the takeaway is that medical and legal evidence move together. The same trial data that gives a newly diagnosed patient more time gives that patient's attorney a stronger damages argument. That is not a coincidence — it is what current standard of care looks like in mesothelioma in 2026.

"We tell newly diagnosed clients two things in the first meeting. One: there are treatment options today that did not exist in 2019, and we want them to have access to all of them. Two: the same data that supports those treatment options also supports their legal recovery. We do not separate the two conversations because they are the same conversation."

— Paul Danziger, Founding Partner, Danziger & De Llano

Frequently Asked Questions

How has mesothelioma life expectancy changed for damages calculations in 2026?

Pre-2020 actuarial projections for unresectable pleural mesothelioma assumed median overall survival of approximately 12 months and a 5-year survival rate under 5%. The 2026 5-year update from the CheckMate 743 trial published in the Journal of Clinical Oncology reports a 14% five-year overall survival rate with first-line nivolumab plus ipilimumab [1] — more than double the chemotherapy comparator and substantially higher than the historic baseline. Damages projections built on the older numbers systematically understate the duration of lost earnings, future medical costs, and pain-and-suffering damages.

What does ATOMIC-Meso add to damages calculations for nonepithelioid mesothelioma plaintiffs?

ATOMIC-Meso (JAMA Oncology, April 2024) is the first positive Phase 3 trial in nonepithelioid pleural mesothelioma, a subtype historically associated with worse outcomes than epithelioid disease. Pegargiminase plus chemotherapy produced median overall survival of 9.3 months versus 7.7 months with placebo plus chemotherapy — a hazard ratio for death of 0.71, or a 29% reduction in the risk of death [2]. For damages experts working with sarcomatoid or biphasic plaintiffs, that benefit needs to be incorporated rather than relying on pre-trial pessimistic projections.

Do defense damages experts still use outdated mesothelioma survival data?

It happens regularly. Defense damages experts often anchor mesothelioma life-expectancy testimony to pre-2020 SEER survival statistics or to the Vogelzang 2003 trial that established pemetrexed plus cisplatin [4]. Those references predate every major immunotherapy approval and predate ATOMIC-Meso entirely. A plaintiff attorney whose damages expert uses 2026 data while opposing counsel uses 2003 data has a substantial credibility advantage on the future-care and lost-earnings line items.

How much can extended life expectancy add to a mesothelioma settlement?

It depends on the patient's age at diagnosis, occupation, dependents, and treatment status, but the order of magnitude is meaningful. A 65-year-old plaintiff whose damages expert projects 12 months of remaining life expectancy will calculate one set of lost-earnings, future-medical, and pain-and-suffering numbers; the same patient projected at 24–36 months on current immunotherapy outcomes will produce damages totals materially higher across every category. Multiplied across multiple defendants and trust fund claims, the difference is frequently in the hundreds of thousands of dollars.

Do CheckMate 743 and ATOMIC-Meso change asbestos trust fund recoveries?

Trust fund schedules typically pay flat amounts per disease tier, so the headline trust fund payouts do not move with new survival data. The legal recovery on the civil-litigation side does. Civil settlements and verdicts incorporate damages projections that draw on current medical evidence, and that is where the 2026 survival data lands hardest. Outcomes vary by case, and several states (TX, OH, WV, WI, AZ, MS) apply statutory setoffs and trust-disclosure rules that affect how parallel trust and civil recoveries interact with civil verdicts; experienced plaintiff counsel handles the disclosure and apportionment work in each jurisdiction.

References

1. Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, Peters S, Mansfield AS, Popat S, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. Journal of Clinical Oncology. 2026;44(9):742-749. doi:10.1200/JCO-25-01328. PMID: 41734361.
2. Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, et al. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncology. 2024;10(4):475-483. doi:10.1001/jamaoncol.2023.6789. PMID: 38358753.
3. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8. PMID: 33485464.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.136. PMID: 12860938.
5. Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France (IND.227): a phase 3, open-label, randomised controlled trial. The Lancet. 2023;402(10419):2295-2306. doi:10.1016/S0140-6736(23)01613-6. PMID: 37931632.
6. Cancer Stat Facts: Mesothelioma. Surveillance, Epidemiology, and End Results Program. National Cancer Institute.
7. FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma. U.S. Food and Drug Administration. October 2, 2020.
8. Asbestos exposure compensation. U.S. Department of Veterans Affairs.
9. Asbestos Toxicological Profile. Agency for Toxic Substances and Disease Registry.
10. Mesothelioma — Patient Version. National Cancer Institute.